Literature DB >> 7847932

Present status and potential role of high-dose adjuvant chemotherapy in breast cancer with poor prognosis.

B Thürlimann1.   

Abstract

Entities:  

Mesh:

Year:  1994        PMID: 7847932     DOI: 10.1007/bf02389261

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


× No keyword cloud information.
  5 in total

1.  Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.

Authors:  W P Sheridan; C G Begley; C A Juttner; J Szer; L B To; D Maher; K M McGrath; G Morstyn; R M Fox
Journal:  Lancet       Date:  1992-03-14       Impact factor: 79.321

Review 2.  Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer.

Authors:  B Fisher; D L Wickerham; C Redmond
Journal:  Semin Oncol       Date:  1992-06       Impact factor: 4.929

3.  Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

Authors:  J Crawford; H Ozer; R Stoller; D Johnson; G Lyman; I Tabbara; M Kris; J Grous; V Picozzi; G Rausch
Journal:  N Engl J Med       Date:  1991-07-18       Impact factor: 91.245

4.  Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial.

Authors:  C Focan; J M Andrien; M T Closon; M Dicato; P Driesschaert; D Focan-Henrard; M Lemaire; J P Lobelle; L Longree; F Ries
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

5.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

Authors:  W P Peters; M Ross; J J Vredenburgh; B Meisenberg; L B Marks; E Winer; J Kurtzberg; R C Bast; R Jones; E Shpall
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.